Insulin medicines: Evolution
Timeline
The milestones of the product, each with a source
| Year | Event |
|---|---|
| 1923 | Eli Lilly begins selling Iletin, the first commercially available insulin product [3][4] |
| 1982 | The FDA approves Humulin, human insulin made by bacteria and the first FDA-approved recombinant drug of any kind [3] |
| 1996 | Humalog, the first rapid insulin analogue, is produced [5] |
| 2021 | WHO reports that three multinational companies control more than 90% of the insulin market; the UK PenCycle pen-return pilot starts in November [1][16] |
| 2022 | WHO prequalifies the first human insulins (Novo Nordisk), on 28 September [7] |
| 2026 | A once-weekly basal insulin, Awiqli, is on sale in India, and a press report says Novo Nordisk is withdrawing human insulin in Penfill cartridges and FlexPen devices there [10] |
as of 2026-11-13
Recipe changes
How what it is made of changed over time, and what drove each change
| Change | From | To | Driver | Source |
|---|---|---|---|---|
| What makes the insulin | Early insulins such as Iletin of 1923 [4]; pig insulin was later turned into human insulin with an enzyme [6] | Human insulin made by bacteria (Humulin, approved 1982) | The ACS booklet says bacteria make human insulin at 98% purity [3] | [3][4][6] |
| The molecule | Human insulin | Analogues, first the rapid analogue Humalog in 1996 | Faster action; the sources opened give no other reason | [5] |
| How often the dose is given | Once-daily basal insulin, 22 pens a patient a year (France, modelled) | Once-weekly basal insulin, 5 pens a patient a year (France, modelled) | Fewer injections and pens [14] | [14] |
as of 2026-11-13
What could improve it next
Directions for improvement, today's value and the limit
| Direction | Metric | Today | Unit | Source |
|---|---|---|---|---|
| Once-weekly basal insulin | Pens used per patient in a year | 5 | pens per year (22 for once-daily; no limit stated) | [14] |
| Insulin that tolerates warmth | Weeks allowed at up to 30 degrees C before opening (human insulin, Novo Nordisk) | 4 | weeks (no limit stated) | [7] |
| Reach people who need insulin but do not get it | Share of people with type 2 diabetes needing insulin who do not get it | 50 | % (one in two, calculated; no limit stated) | [1] |
as of 2026-11-13
Sources
- New WHO report maps barriers to insulin availability and suggests actions to promote universal access World Health Organization, 2021, news item of 12 November 2021
- Insulin Development and Commercialization American Chemical Society (National Historic Chemical Landmark), 2023, landmark booklet, © 2023 American Chemical Society
- Manufactured insulin, 'Iletin', United States, 1923 | Science Museum Group Collection Science Museum Group, object record co143500
- 100 Years since the Discovery of Insulin, from Its Discovery to the Insulins of the Future Biomedicines (MDPI), on PubMed Central, 2024
- Insulin: Recombinant Production, Sustainability, and Chemistry Oxford Global (article by Tom Cohen on a presentation by Thomas Høeg-Jensen, Scientific Director at Novo Nordisk), 2023, page of 25 April 2023
- First human insulins prequalified World Health Organization, Prequalification of Medical Products, 2022, news item of 28 September 2022
- India 2030: Who Supplies the Next 10 Million? BioSpectrum India (Ankit Kankar), 2026, article of 1 November 2026
- Environmental Impact of Switching from Daily to Weekly Basal Insulin Administration in France ISPOR Europe 2024 abstract EE212 (Bellier L, Antier C, Soggiu M, Virely N, Laporte L, Sivignon M, Kind B; affiliations Putnam, Paris, and Novo Nordisk, Paris), Value in Health 27(12) S2, 2024
- Patients return 200,000 injection pens through recycling scheme The Pharmaceutical Journal (David Lipanovic), 2023, article of 15 August 2023